| abstract |
A pharmaceutically acceptable salt, crystal form and preparation method of an OTR inhibitor are provided. Specifically, an OTR inhibitor 5-(3-(3-(6-fluoronaphthalene-1-yl)azetidine-1-yl)-5-(methoxymethyl)- 4H-1,2,4-triazole-4-yl)-2-methoxypyridine pharmaceutically acceptable salt, crystal form and preparation method. The pharmaceutically acceptable salt improves the free base dissolution rate and the physical or chemical stability of the OTR inhibitor, and is of great significance for the development of drugs suitable for industrial production and good biological activity. |